Poster Abstracts
Grand Hall CD (Manchester Grand Hyatt)
Ixazomib Inhibits Dendritic Cell Maturation and Function
A. Samer Al-Homsi, MD, Spectrum Health;
Kendall Locke, Spectrum Health;
Kelli Cole, RN, MSN, Spectrum Health;
Marlee Bogema, RN, BSN, Spectrum Health;
Yuxin Feng, PhD, Spectrum Health
Short Course of Post-Transplant Cyclophosphamide and Bortezomib for the Prevention of Graft-Versus-Host-Disease after Matched Related or Unrelated Donor Blood or Marrow Transplant
A. Samer Al-Homsi, MD, Michigan State University;
Tara S Roy, MS, RNP, Spectrum Health;
Kelli Cole, RN, MSN, Spectrum Health;
Marlee Bogema, RN, BSN, Spectrum Health;
Ulrich Duffner, MD, Helen DeVos Children's Hospital;
Stephanie F Williams, MD, Michigan State University;
Aly A Mageed, MD, Helen DeVos Children's Hospital
Graft Versus Leukemia Effect Is Overestimated in Studies with High Rates of Graft Versus Host Disease Related Mortality: A Simulation Study
Murtadha Al-Khabori, MD, MSc, FRCPC, Sultan Qaboos University Hospital;
Mohammed Al Huneini, MD, Sultan Qaboos University Hospital;
Khalil Al Farsi, MD, FRCPC, Sultan Qaboos University Hospital;
Salam Al Kindi, MD, Sultan Qaboos University Hospital;
David Dennison, Sultan Qaboos University Hospital;
Abdulhakeem Al Rawas, MD, Sultan Qaboos University Hospital;
Yaser Wali, MD, Sultan Qaboos University Hospital
Acute Skin Graft Versus Host Disease Post Liver Transplantation: A Case Report
Mohammad Alhyari, M.D., Henry Ford Hospital;
Aymen Bukannan, M.D., Henry Ford Hospital;
Kimberly Brown, M.D., Henry Ford Hospital;
Shatha Farhan, M.D., Henry Ford Hospital;
Edward Peres, M.D., Henry Ford Hospital;
Nalini Janakiraman, M.D., Henry Ford Hospital
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Stem Cell Transplantation
Sally Arai, MD, Stanford University Medical Center;
Joseph Pidala, MD, PhD, H. Lee Moffitt Cancer Center and Research Institute;
Iskra Pusic, MD, Washington University Medical Center;
Xiaoyu Chai, MS, Fred Hutchinson Cancer Research Center;
Samantha Jaglowski, MD, MPH, The Ohio State University Medical Center;
Jeanne Palmer, MD, Mayo Clinic Arizona;
George L Chen, MD, Roswell Park Cancer Institute;
Nandita Khera, MD, Mayo Clinic Arizona;
Sebastian Mayer, MD, Weill Cornell Medical Center;
Madan H. Jagasia, MD, MBBS, MS, Vanderbilt University Medical Center;
William A. Wood, MD, MPH, University of North Carolina - Chapel Hill;
Paul J. Martin, MD, Fred Hutchinson Cancer Research Center;
Yoshihiro Inamoto, MD PhD, Fred Hutchinson Cancer Research Center;
David B. Miklos, Stanford University Medical Center;
Stephanie J. Lee, MD, MPH, Fred Hutchinson Cancer Research Center;
Mary E. D. Flowers, MD, Fred Hutchinson Cancer Research Center
Analysis of Risk Factors for Hepatic Acute Graft-Versus-Host Disease By Using Transplant Registry Data in Japan
Yasuyuki Arai, MD, Graduate School of Medicine, Kyoto University;
Junya Kanda, MD, Saitama Medical Center, Jichi Medical University;
Hideki Nakasone, Saitama Medical Center, Jichi Medical University;
Tadakazu Kondo, MD, Graduate School of Medicine, Kyoto University;
Naoyuki Uchida, MD, PhD, Toranomon Hospital;
Takahiro Fukuda, MD, PhD, National Cancer Center Hospital;
Kazuteru Ohashi, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital;
Hiroyasu Ogawa, MD, PhD, Hyogo College of Medicine;
Tokiko Nagamura-Inoue, MD, The Institute of Medical Science, The University of Tokyo;
Yasuo Morishima, MD, Aichi Cancer Center Research Institute;
Makoto Hirokawa, MD, Graduate School of Medicine, Akita University;
Yoshiko Atsuta, MD, PhD, Nagoya University Graduate School of Medicine;
Makoto Murata, MD, Nagoya University Graduate School of Medicine
Chronic Graft Vs. Host Disease of the CNS - a Rare Autopsied Case
Amy E Armstrong, MD, Ann & Robert H. Lurie Children's Hospital of Chicago;
Nitin Ramesh Wadhwani, M.D., Ann & Robert H. Lurie Children’s Hospital of Chicago;
Craig Smith, M.D., Ann & Robert H. Lurie Children’s Hospital of Chicago;
Maura Ryan, M.D., Ann & Robert H. Lurie Children’s Hospital of Chicago;
Sudhi Kurup, M.D., Ann & Robert H. Lurie Children’s Hospital of Chicago;
Jennifer Schneiderman, MD, MS, Ann & Robert H. Lurie Children's Hospital of Chicago
Single Nucleotide Gene Polymorphisms (SNP) in the Gamma Block of the Major Histocompatibility Complex (MHC) Are Independent Risk Factors for Severe Acute Graft Versus Host Disease (GVHD) in Unrelated Donor Hematopoietic Cell Transplantation (HCT)
Medhat Askar, MD, PhD, Cleveland Clinic;
Navneet S. Majhail, MD, MS, Cleveland Clinic;
Lisa Rybicki, MS, Cleveland Clinic Taussig Cancer Institute;
Aiwen Zhang, PhD, Cleveland Clinic;
Dawn Thomas, BS, Cleveland;
Dongxing Chen, MS, Cleveland Clinic;
Donna Abounader, CCRP, Cleveland Clinic;
Brian Bolwell, MD, Cleveland Clinic;
Robert M Dean, MD, Cleveland Clinic;
Hien K. Duong, MD, Cleveland Clinic;
Aaron Gerds, MD, Cleveland Clinic;
Betty Hamilton, Cleveland Clinic;
Rabi Hanna, MD, Cleveland Clinic;
Brian Hill, MD, PhD, Cleveland Clinic;
Deepa Jagadeesh, MD, MPH, Umass Medical School;
Brad Pohlman, MD, Cleveland Clinic;
Matt E. Kalaycio, MD, Cleveland Clinic;
David Sayer, PhD, Conexio Genomics;
Ronald Sobecks, MD, Taussig Cancer Institute, Cleveland Clinic
Evaluation of Donor KIR2DL1 Allelic Polymorphism in the Setting of T-Cell Repleted Haploidentical Transplantation
Mariana Bastos-Oreiro, MD, HGU Gregorio Marañón;
Carolina Martinez-Laperche, PhD, HGU Gregorio Marañón;
Laura Solan, MD, HGU Gregorio Marañón;
Diego Carbonell, HGU Gregorio Marañón;
Javier Anguita, HGU Gregorio Marañón;
Ana Pérez-Corral, HGU Gregorio Marañón;
Cristina Pascual, HGU Gregorio Marañón;
Mi Kwon, HGU Gregorio Marañón;
David Serrano, HGU Gregorio Marañón;
Jorge Gayoso, HGU Gregorio Marañón;
Elena Buces, HGU Gregorio Marañón;
Ismael Buño, HGU Gregorio Marañón;
Pascual Balsalobre, HGU Gregorio Marañón;
José Luis Diez-Martin, HGU Gregorio Marañón
T Regulatory Cell Kinetics Are Altered in a Target Organ of Chronic Gvhd, Resulting in a Low T Regulatory to T Effector Memory Cell Ratio
Nataliya Prokopenko Buxbaum, MD, NIH, NCI;
Donald Eugene Farthing, PhD, NIH, NCI;
Andrea Carpenter Boehrer, PhD, NIH, NCI;
Veena Kapoor, BS, NIH, NCI;
Ehydel Castro, MD, NIH, NCI;
Nicolas Jean Bouladoux, PhD, NIH, NIAID;
Gregory Swan, BS, NIH, NCI;
William Telford, PhD, NIH, NCI;
Michael Eckhaus, DVM, NIH, NCI;
Yasmine Belkaid, PhD, NIH, NIAID;
Remy Bosselut, MD, PhD, NIH, NCI;
Ronald Gress, MD, * Co-Senior Experimental Transplantation and Immunology Branch/NCI/NIH
Predictive Models Using NIH Criteria and Clinical Characteristics Define Diagnosis, Disease Activity and Risk Factors for Chronic Ocular Graft-Versus Host Disease
Lauren M. Curtis, MD, National Cancer Institute, National Institutes of Health;
Manuel B. Datiles III, MD, National Eye Institute, NIH;
Seth M. Steinberg, PhD, National Cancer Institute, National Institutes of Health;
Rachel J. Bishop, MD, National Eye Institute, NIH;
Edward W. Cowen, MD, National Cancer Institute, NIH;
Jacqueline Mays, DDS, National Institute of Dental and Craniofacial Research, NIH;
Filip Pirsl, B.Sc, National Cancer Institute, National Institutes of Health;
Judy L. Baruffaldi, BA, National Cancer Institute, National Institutes of Health;
Jennifer Hsu, RN, ETIB/NCI/NIH;
Sandra A. Mitchell, PhD, CRNP, National Cancer Institute, NIH;
Steven Z. Pavletic, MD, National Cancer Institute, National Institutes of Health
Leukapheresis Safely and Effectively Yields Lymphocyte Populations Sufficient for Chronic Gvhd Research
Lauren M. Curtis, MD, National Cancer Institute, National Institutes of Health;
Cathy Cantilena, MD, Department of Transfusion Medicine, Clinical Center, National Institutes of Health;
Yu Ying Yau, RN, Department of Transfusion Medicine, Clinical Center, National Institutes of Health;
Tracey Chinn, RN, Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health;
Jennifer Hsu, RN, ETIB/NCI/NIH;
Filip Pirsl, B.Sc, National Cancer Institute, National Institutes of Health;
Judy L. Baruffaldi, BA, National Cancer Institute, National Institutes of Health;
Fran Hakim, PhD, National Cancer Institute, National Institutes of Health;
Daniel Fowler, MD, National Cancer Institute, National Institutes of Health;
Ronald Gress, MD, * Co-Senior Experimental Transplantation and Immunology Branch/NCI/NIH;
Steven Z. Pavletic, MD, National Cancer Institute, National Institutes of Health
T-Cell Transcriptome Analysis Reveals the Mechanisms Controlling Synergy Between Costimulation Blockade and mTOR Inhibition during Gvhd Prevention
Scott N Furlan, MD, Seattle Children's Research Institute;
Benjamin K. Watkins, MD, Emory University;
Angela Mortari, University of Minnesota;
Bruce R. Blazar, MD, University of Minnesota;
Leslie S. Kean, MD, PhD, Fred Hutchinson Cancer Research Center
Second Allogeneic Hematopoietic Cell Transplantation Versus Donor Cellular Infusion for Relapse after Transplant
Betty Ky Hamilton, MD, Cleveland Clinic;
Shylaja Mani, MD, Cleveland Clinic foundation;
Lisa Rybicki, MS, Cleveland Clinic Taussig Cancer Institute;
Donna Abounader, CCRP, Cleveland Clinic;
Steven Andresen, DO, Cleveland Clinic;
Brian Bolwell, MD, Cleveland Clinic;
Robert M Dean, MD, Cleveland Clinic;
Hien K. Duong, MD, Cleveland Clinic;
Aaron Gerds, MD, MS, Cleveland Clinic;
Rabi Hanna, MD, Cleveland Clinic;
Brian Hill, MD, PhD, Cleveland Clinic;
Deepa Jagadeesh, MD, MPH, Cleveland Clinic;
Matt E. Kalaycio, MD, Cleveland Clinic;
Brad Pohlman, MD, Cleveland Clinic;
Ronald Sobecks, MD, Cleveland Clinic;
Navneet S. Majhail, MD, MS, Cleveland Clinic
Liver Transplantation for Hepatic Graft-Versus-Host-Disease: A United Network for Organ Sharing (UNOS) Database Study
Shahrukh Hashmi, MD, MPH, Mayo Clinic Rochester;
Timucin Taner, MD PhD, Mayo Clinic;
Mrinal Patnaik, MBBS, Mayo Clinic;
Michael Leise, MD, Mayo Clinic;
Matthew Hathcock, MS, Mayo Clinic;
Walter K. Kremers, PhD, Mayo Clinic;
William Hogan, MBBCh, Mayo Clinic;
Mark R. Litzow, MD, Mayo Clinic Rochester
A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies
Brad Haverkos, MD, James Cancer Center, Ohio State Medical Center;
Katie Cortright, James Cancer Center, Ohio State Medical Center;
Leslie A Andritsos, MD, James Cancer Center, Ohio State Medical Center;
William Blum, MD, James Cancer Center, Ohio State Medical Center;
Rebecca Klisovic, MD, James Cancer Center, Ohio State Medical Center;
Sumithira Vasu, MBBS, James Cancer Center, Ohio State Medical Center;
David M. Goldenberg, ScD, MD, Immunomedics, Inc.;
William Wegener, MD, PhD, Immunomedics, Inc.;
Steven M. Devine, MD, James Cancer Center, Ohio State Medical Center;
Samantha Jaglowski, MD, MPH, James Cancer Center, Ohio State Medical Center
Pharamacodynamic Assessment Shows That CCR5 Surface Expression May Serve As an Indicator for Effective CCR5 Blockade in Allogeneic Stem Cell Transplant (alloSCT) Recipients Treated with Maraviroc
Austin P. Huffman, BA, Perelman School of Medicine at the University of Pennsylvania;
Lee P Richman, BA, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania;
David L. Porter, MD, Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania;
Robert H Vonderheide, MD DPhil, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania;
Ran Reshef, MD, Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania
CD4+CD25+ Invariant Natural Killer T Cells Are Enriched in Cord Blood: Implication on Immune-Regulation
Jin Seon Im, M.D., Ph.D., The University of Texas MD Anderson Cancer Center;
Irina Fernandez, Ph.D., The University of Texas MD Anderson Cancer Center;
Gurdyal Besra, Ph.D., The Universtiy of Birmingham;
Steven Porcelli, Albert Einstein College of Medicine;
Katy Rezvani, MD, The University of Texas MD Anderson Cancer Center;
Elizabeth J. Shpall, MD, The University of Texas MD Anderson Cancer Center;
Jeffrey Molldrem, MD, The University of Texas MD Anderson Cancer Center
The MEK Inhibitior Trametinib Selectively Suppresses Gvhd, While Sparing GVT Effects
Hidekazu Itamura, M.D., Saga University;
Takero Shindo, M.D., Ph.D., Saga University;
Isao Tawara, M.D., Ph.D., Mie University Hospital;
Ryusho Kariya, M.S., Kumamoto University;
Seiji Okada, M.D., Ph.D., Kumamoto University;
Krishna V. Komanduri, MD, University of Miami, Sylvester Comprehensive Cancer Center;
Shinya Kimura, M.D., Ph.D., Saga University
Plasma-Derived Proteomic Biomarkers Have Prognostic Utility in Patients Treated with Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis for HLA-Matched Allogeneic Bone Marrow Transplantation
Christopher G. Kanakry, MD, The Johns Hopkins University School of Medicine;
Susan M. Perkins, PhD, Indiana University;
Etienne Daguindau, MD, Indiana University;
Ante Vulic, MD, The Johns Hopkins University School of Medicine;
Taylor Olmsted, MD, Indiana University;
Christen Mumaw, MS, Indiana University;
Shannon R. McCurdy, MD, The Johns Hopkins University School of Medicine;
Heather J. Symons, MD, MHS, The Johns Hopkins University School of Medicine;
Andrea M. Towlerton, BS, Fred Hutchinson Cancer Research Center;
Edus H. Warren, MD, PhD, Fred Hutchinson Cancer Research Center;
Paul V. O'Donnell, MD, PhD, FACP, Fred Hutchinson Cancer Research Center;
Sophie Paczesny, MD, PhD, Indiana University;
Leo Luznik, MD, The Johns Hopkins University School of Medicine
CD155 Regulates Regulatory T Cell Population and Attenuates Acute Graft-Versus-Host Disease
Minoru Kanaya, MD, Hokkaido University Graduate School of Medicine;
Kazuko Shibuya, MD, University of Tsukuba;
Fumie Abe, University of Tsukuba;
Takanori Teshima, MD, PhD, Hokkaido University Graduate School of Medicine;
Akira Shibuya, MD, University of Tsukuba
Impact of Acute and Chronic Graft-Versus-Host Disease on Outcomes after Single Cord Blood Transplantation: A Retrospective Analysis By the JSHCT Gvhd Working Group
Junya Kanda, MD, Saitama Medical Center, Jichi Medical University;
Yasuo Morishima, MD, Aichi Cancer Center Research Institute;
Atsushi Wake, MD, PhD, Toranomon Hospital;
Seitaro Terakura, MD, Nagoya University Graduate School of Medicine;
Naoyuki Uchida, MD, PhD, Toranomon Hospital;
Satoshi Takahashi, MD, The Institute of Medical Science, The University of Tokyo;
Yuju Ono, MD, Kitakyushu Municipal Medical Center;
Yasushi Onishi, MD, Tohoku University Hospital;
Heiwa Kanamori, MD, Kanagawa Cancer Center;
Nobuyuki Aotsuka, MD, Japanese Red Cross Society Narita Hospital;
Koji Kato, MD, Japanese Red Cross Nagoya First Hospital;
Yoshiko Atsuta, MD, PhD, Nagoya University Graduate School of Medicine;
Makoto Murata, MD, Nagoya University Graduate School of Medicine
Prospective Longitudinal Study of Late Acute Graft Versus Host Disease after Hematopoietic Cell Transplantation: A Report from Chronic Gvhd Consortium
Nandita Khera, MD, Mayo Clinic;
Xiaoyu Chai, MS, Fred Hutchinson Cancer Research Center;
Hien K. Duong, MD, Cleveland Clinic;
Yoshihiro Inamoto, MD PhD, National Cancer Center Hospital;
George L Chen, MD, Roswell Park Cancer Institute;
Sebastian Mayer, MD, Weill Cornell Medical Center;
Mukta Arora, MD, MS, University of Minnesota Medical Center;
Jeanne Palmer, MD, Mayo Clinic Arizona;
Mary E. D. Flowers, MD, Fred Hutchinson Cancer Research Center;
Corey S. Cutler, MD, Dana-Farber Cancer Institute, Harvard Medical School;
Alexander Lukez, Dana Farber Cancer Institute;
Sally Arai, MD, Stanford University Medical Center;
Aleksandr Lazaryan, MD MPH PhD, University of Minnesota Medical Center;
Madan H. Jagasia, MD, MBBS, MS, Vanderbilt University Medical Center;
Iskra Pusic, MD, Washington University Medical Center;
William Wood, MD, MPH, University of North Carolina Healthcare;
Stephanie J. Lee, MD, MPH, Fred Hutchinson Cancer Research Center;
Joseph Pidala, MD, PhD, H. Lee Moffitt Cancer Center and Research Institute
Phase II Clinical Trial of Etanercept Plus Extracorporeal Photopheresis Gvhd Prophylaxis Following Unrelated Donor Reduced Intensity Transplant
Carrie L. Kitko, MD, University of Michigan;
Thomas Braun, PhD, University of Michigan;
Charles Schuler, MD, University of Michigan;
Sung Won Choi, M.D., University of Michigan;
Gregory Yanik, MD, University of Michigan;
Attaphol Pawarode, MD, University of Michigan;
John Magenau, M.D., University of Michigan;
Austin Taylor, Icahn School of Medicine at Mount Sinai;
James L. M. Ferrara, MD, DSc, Icahn School of Medicine at Mount Sinai;
Daniel R. Couriel, MD, MS, University of Michigan;
John Levine, MD, MS, University of Michigan
Overall Survival (OS) of Pediatric Patients with Moderate to Severe Chronic Graft Vs. Host Disease (CGVHD). a Single Institution Experience
Morris Kletzel, MD, FAAP, MBA, Northwestern University Feinberg School of Medicine;
Kyle Kauffman, Lurie Children's Hospital of Chicago;
Kimberly Powers, APN, NP, Lurie Children's Hospital of Chicago;
Reggie E Duerst, MD, Ann & Robert H. Lurie Children's Hospital of Chicago;
Sonali Chaudhury, MD, Ann & Robert H. Lurie Children's Hospital of Chicago;
Jennifer Schneiderman, MD, MS, Ann & Robert H. Lurie Children's Hospital of Chicago;
William T Tse, MD, PhD, Children's Memorial Research Center;
Sana Khan, Medical Student, Ann & Robert H. Lurie Children's Hospital of Chicago
Treatment with Human Mesenchymal Stem Cells (Remestemcel-L) Is Effective in Pediatric Patients with Refractory Acute Graft Versus Host Disease
Joanne Kurtzberg, MD, Duke University Medical Center;
Susan E. Prockop, MD, Memorial Sloan Kettering Cancer Center;
Vinod K. Prasad, MD, Duke University Medical Center;
Sonali Chaudhury, MD, Ann & Robert H. Lurie Children's Hospital of Chicago;
Pierre Teira, MD, MSc, CHU Sainte Justine;
Eneida R Nemecek, MD, Oregon Health & Science University;
Biljana Horn, MD, UCSF Benioff Children's Hospital;
Elizabeth Burke, Mesoblast;
Jack Hayes, Mesoblast;
Donna Skerrett, MD, MS, Mesoblast
Dnase I Treatment Reduces Gvhd in Mice
Dan Li, PhD, University of Texas M.D. Anderson Cancer Center;
Rebecca Patenia, BS, UT M.D. Anderson Cancer Center;
Roland Bassett Jr., MS, The University of Texas MD Anderson Cancer Center;
George Tetz, CLS Therapeutics;
Richard E. Champlin, MD, The University of Texas MD Anderson Cancer Center;
Qing Ma, PhD, M.D. Anderson Cancer Center
Early Apoptotic Cells (ApoCell) As Prophylaxis of Graft-Versus-Host Disease Is Safe and Effective: 1 Year Follow-up and Mechanism of Action
Dror Mevorach, Hadassah-Hebrew University;
Tzila Zuckerman, Rambam;
Avichai Shimoni, MD, BMT Department;
Reuven Or, MD, Hadassah University Hospital;
Jacob M. Rowe, MD, Rambam Medical Center;
Arnon Nagler, MD, The Chaim Sheba Medical Center, Tel-Hashomer, Division of Hematology and Bone Marrow Transplantation;
Ina Reiner, Hadassah-Hebrew University
Risks and Benefits of Sex-Mismatched Hematopoietic Cell Transplantation Differ By Conditioning Strategy
Hideki Nakasone, Stanford University School of Medicine;
Mats Remberger, PhD, Karolinska University Hospital;
Lu Tian, Stanford University School of Medicine;
Petter Brodin, Karolinska Institutet;
Bita Sahaf, Stanford University School of Medicine;
Fang Wu, Stanford University School of Medicine;
Jonas Mattsson, MD PhD, Karolinska University Hospital;
Robert Lowsky, MD, Stanford University School of Medicine;
Robert Negrin, MD, Stanford University School of Medicine;
David B. Miklos, Stanford University School of Medicine;
Everett Meyer, MD, PhD, Stanford University School of Medicine
The Impact of Histologic Grade on Acute Graft Versus Host Disease Response and Outcomes
Mayur Narkhede, MD, Cleveland Clinic;
Lisa Rybicki, MS, Cleveland Clinic Taussig Cancer Institute;
Donna Abounader, CCRP, Cleveland Clinic;
Steven Andresen, DO, Cleveland Clinic;
Brian Bolwell, MD, Cleveland Clinic;
Robert M Dean, MD, Cleveland Clinic;
Hien K. Duong, MD, Cleveland Clinic;
Aaron Gerds, MD, MS, Cleveland Clinic;
Rabi Hanna, MD, Cleveland Clinic;
Brian Hill, MD, PhD, Cleveland Clinic;
Deepa Jagadeesh, MD, MPH, Cleveland Clinic;
Matt E. Kalaycio, MD, Cleveland Clinic;
Brad Pohlman, MD, Cleveland Clinic;
Ronald Sobecks, MD, Cleveland Clinic;
Navneet S. Majhail, MD, MS, Cleveland Clinic;
Betty Ky Hamilton, MD, Cleveland Clinic
Late Onset Acute Gvhd (late aGVHD) after Allogeneic Hematopoietic Stem Cell Transplantation (HCT)
Aazim Omer, MD, University of Minnesota Medical Center;
Daniel J. Weisdorf, MD, University of Minnesota Medical Center;
Aleksandr Lazaryan, MD MPH PhD, University of Minnesota Medical Center;
Ryan Shanley, M.S., University of Minnesota Medical Center;
Bruce R. Blazar, MD, University of Minnesota;
Margaret L. MacMillan, MD, MSc, FRCPC, University of Minnesota;
Claudio G. Brunstein, MD, PhD, University of Minnesota Medical Center;
Nelli Bejanyan, MD, University of Minnesota Medical Center;
Mukta Arora, MD, MS, University of Minnesota Medical Center
A Review of Radiographic Findings in Gvhd
Michael Bernhard Osswald, MD, San Antonio Military Medical Center;
Alexander W. Brown, MD, MAJ, USA, MC, San Antonio Military Medical Center;
Michael A. Wiggins, MD, LTC, USA, MC, San Antonio Military Medical Center;
Russell A Baur, MD, San Antonio Military Medical Center;
John S. Renshaw, MD, Lt Col, USAF, MC, San Antonio Military Medical Center
Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft Vs. Host Disease
Joseph Pidala, MD, PhD, H. Lee Moffitt Cancer Center and Research Institute;
Jongphil Kim, PhD, H. Lee Moffitt Cancer Center and Research Institute;
Binglin Yue, MS, H. Lee Moffitt Cancer Center and Research Institute;
Brian Betts, MD, H. Lee Moffitt Cancer Center and Research Institute;
Melissa Alsina, MD, H. Lee Moffitt Cancer Center and Research Institute;
Ernesto Ayala, MD, H. Lee Moffitt Cancer Center and Research Institute;
Hugo Fernandez, MD, H. Lee Moffitt Cancer Center and Research Institute;
Teresa Field, MD, PhD, H. Lee Moffitt Cancer Center and Research Institute;
Linda Kelley, PhD, H. Lee Moffitt Cancer Center and Research Institute;
Mohamed Kharfan-Dabaja, MD, H. Lee Moffitt Cancer Center and Research Institute;
Frederick L Locke, MD, H. Lee Moffitt Cancer Center and Research Institute;
Asmita Mishra, MD, H. Lee Moffitt Cancer Center and Research Institute;
Michael L. Nieder, MD, H. Lee Moffitt Cancer Center and Research Institute;
Taiga Nishihori, MD, H. Lee Moffitt Cancer Center and Research Institute;
Jose-Leonel Ochoa-Bayona, MD, H. Lee Moffitt Cancer Center and Research Institute;
Lia Elena Perez, MD, H. Lee Moffitt Cancer Center and Research Institute;
Marcie L. Riches, MD, MS, H. Lee Moffitt Cancer Center and Research Institute;
Claudio Anasetti, MD, H. Lee Moffitt Cancer Center and Research Institute
IL-12/23p40 Neutralization in Combination with Sirolimus for Prevention of Acute Graft Vs. Host Disease
Joseph Pidala, MD, PhD, H. Lee Moffitt Cancer Center and Research Institute;
Francisca Beato, BS, H. Lee Moffitt Cancer Center and Research Institute;
Jongphil Kim, PhD, H. Lee Moffitt Cancer Center and Research Institute;
Melissa Alsina, MD, H. Lee Moffitt Cancer Center and Research Institute;
Ernesto Ayala, MD, H. Lee Moffitt Cancer Center and Research Institute;
Brian Betts, MD, H. Lee Moffitt Cancer Center and Research Institute;
Hugo Fernandez, MD, H. Lee Moffitt Cancer Center and Research Institute;
Teresa Field, MD, PhD, H. Lee Moffitt Cancer Center and Research Institute;
Heather Jim, PhD, Moffitt Cancer Center;
Linda Kelley, PhD, H. Lee Moffitt Cancer Center and Research Institute;
Mohamed Kharfan-Dabaja, MD, H. Lee Moffitt Cancer Center and Research Institute;
Frederick L Locke, MD, H. Lee Moffitt Cancer Center and Research Institute;
Asmita Mishra, MD, H. Lee Moffitt Cancer Center and Research Institute;
Michael L. Nieder, MD, H. Lee Moffitt Cancer Center and Research Institute;
Taiga Nishihori, MD, H. Lee Moffitt Cancer Center and Research Institute;
Jose-Leonel Ochoa-Bayona, MD, H. Lee Moffitt Cancer Center and Research Institute;
Lia Elena Perez, MD, H. Lee Moffitt Cancer Center and Research Institute;
Marcie L. Riches, MD, MS, H. Lee Moffitt Cancer Center and Research Institute;
Anandaraman Veerapathran, PhD, H. Lee Moffitt Cancer Center and Research Institute;
Claudio Anasetti, MD, H. Lee Moffitt Cancer Center and Research Institute
CD3/CD28 Co-Stimulated Activation of PI3K-mTORC2-AKT Metabolic Programming Augments Granzyme B Expression and Direct Cytotoxicity in Expanded Human iNKT Cells
Ramon I Klein-Geltink, PhD, St. Jude Children's Research Hospital;
Claudia A Alves de Araujo, PhD, St. Jude Children's Research Hospital;
Kelly A Andrews, PhD, St. Jude Children's Research Hospital;
Shuyu E, MD PhD, St. Jude Children's Research Hospital;
Geoff A Neale, PhD, St. Jude Children's Research Hospital;
Christopher A Calabrese, PhD, St. Jude Children's Research Hospital;
Gerard Grosveld, PhD, St. Jude Children's Research Hospital;
Asha Pillai, MD, St Jude Children's Research Hospital
Non-Myeloablative TLI/ATG + Alkylator Conditioning Augments Bidirectional Immune Tolerance Via Regulatory MDSC in a Robust Murine Model of MHC-Mismatched BMT for Beta-Thalassemia
Aman Seth, MS, St. Jude Children's Research Hospital;
Shuyu E, MD PhD, St. Jude Children's Research Hospital;
Hossam Abdelsamed, PhD, St. Jude Children's Research Hospital;
Peter Vogel, DVM, PhD, St. Jude Children's Research Hospital;
Asha Pillai, MD, St Jude Children's Research Hospital
In Landmark Analysis the Severity of Day 100 Acute Graft-Versus-Host Disease (aGVHD) Has No Impact on Long-Term Progression-Free Survival (PFS) after Double-Unit Cord Blood Transplantation (DCBT)
Doris M. Ponce, MD, Memorial Sloan Kettering Cancer Center;
Sean Devlin, PhD, Memorial Sloan Kettering Cancer Center;
Valkal Bhatt, Pharm.D., Memorial Sloan Kettering Cancer Center;
Melissa Pozotrigo, PharmD, BCOP, Memorial Sloan Kettering Cancer Center;
Marissa Lubin, BA, Memorial Sloan Kettering Cancer Center;
Emily Lauer, BS, Memorial Sloan Kettering Cancer Center;
Nancy A. Kernan, MD, Memorial Sloan Kettering Cancer Center;
Andromachi Scaradavou, MD, Memorial Sloan Kettering Cancer Center;
Alan M. Hanash, MD, PhD, Memorial Sloan Kettering Cancer Center;
Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center;
Marcel R. M. van den Brink, MD, PhD, Memorial Sloan Kettering Cancer Center;
James W Young, MD, FACP, Memorial Sloan Kettering Cancer Center;
Sergio A. Giralt, MD, Memorial Sloan-Kettering Cancer Center;
Juliet Barker, MBBS (Hons) FRACP, Memorial Sloan Kettering Cancer Center
Inhaled Cyclosporine Solution for the Treatment of Bronchiolitis Obliterans Following Hematopoietic Stem Cell Transplantation (HSCT) or Lung Transplantation
Enkhtsetseg Purev, MD, National Heart, Lung, and Blood Institute;
Nicole Gormley, MD, National Heart, Lung, and Blood Institute;
Catalina Ramos, BSN, National Heart, Lung, and Blood Institute;
Robert Reger, MS, National Heart, Lung, and Blood Institute;
Xin Tian, PhD, National Heart, Lung, and Blood Institute, NIH;
Elena Cho, RN, National Heart, Lung, and Blood Institute;
Debra Reda, RN, National Institutes of Health;
Clara Chen, MD, National Institutes of Health;
Anthony F. Suffredini, MD, National Institutes of Health;
Richard W. Childs, MD, National Heart, Lung, and Blood Institute
Early Post-Transplant Notch Signaling Activity Is Critical for the Differentiation of Pathogenic Alloantigen-Specific T Cells Mediating Acute Graft-Versus-Host Disease
Vedran Radojcic, MD, University of Michigan;
Jooho Chung, University of Michigan;
Ann Friedman, University of Michigan;
Pavan Reddy, MD, University of Michigan;
Bruce R. Blazar, MD, University of Minnesota;
Leo Luznik, MD, The Johns Hopkins University School of Medicine;
Todd Brennan, MD, Duke University;
Christian Siebel, PhD, Genentech Inc.;
Ivan Maillard, MD, PhD, University of Michigan
Is There a Stronger Graft-Versus-Leukemia Effect Using HLA-Haplo-Identical Donors Compared to HLA-Identical Sibling Donors?
Olle Ringden, MD, PhD, Karolinska Institutet;
Myriam Labopin, MD, EBMT Paris study office / CEREST-TC;
Fabio Ciceri, MD, San Raffaele Scientific Institute;
Arnon Nagler, MD, The Chaim Sheba Medical Center, Tel-Hashomer, Division of Hematology and Bone Marrow Transplantation;
Mohamad Mohty, MD, PhD, Department of Haematology, Saint Antoine Hospital
Decidual Stromal Cells As Treatment for Acute Graft Versus Host Disease
Martin Solders, MD, Karolinska University Hospital;
Tom Erkers, MSc, Karolinska Institutet;
Mats Remberger, PhD, Karolinska Institutet;
Silvia Nava, BSc, Karolinska Institutet;
Pia Molldén, BSc, Karolinska Institutet;
Jonas Mattsson, MD PhD, Karolinska University Hospital;
Helen Kaipe, PhD, Karolinska Institutet;
Olle Ringden, MD, PhD, Karolinska Institutet
Predicted Indirectly Recognizable Hla Epitopes (PIRCHE) Provide a Novel Strategy to Individualize Donor Selection That Optimizes Survival Chances
Kirsten A. Thus, MD, University Medical Center Utrecht;
Jaap-Jan Boelens, MD, PhD, University Medical Center Utrecht;
Arianne de Wildt, University Medical Center Utrecht;
Roel A. de Weger, PhD, University Medical Center Utrecht;
Marc Bierings, MD, PhD, University Medical Center Utrecht;
Eric Spierings, PhD, University Medical Center Utrecht
Response and Survival Following Second-Line Therapy in 113 Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
Bryan Trottier, MD, University of Minnesota;
Daniel J. Weisdorf, MD, University of Minnesota Medical Center;
Todd E Defor, MS, University of Minnesota;
Margaret L. MacMillan, MD, MSc, FRCPC, University of Minnesota
Survival without Progressive Impairment As a Novel Endpoint in Chronic Graft-Versus-Host Disease
William A. Wood, MD, MPH, University of North Carolina - Chapel Hill;
Stephanie J. Lee, MD, MPH, Fred Hutchinson Cancer Research Center;
Xiaoyu Chai, MS, Fred Hutchinson Cancer Research Center;
Mary E. D. Flowers, MD, Fred Hutchinson Cancer Research Center;
Corey S. Cutler, MD, Dana-Farber Cancer Institute, Harvard Medical School;
Yoshihiro Inamoto, MD PhD, Fred Hutchinson Cancer Research Center;
Aleksandr Lazaryan, MD MPH PhD, University of Minnesota Medical Center;
Joseph Pidala, MD, PhD, H. Lee Moffitt Cancer Center and Research Institute;
Jeanne Palmer, MD, Mayo Clinic Arizona;
Paul J. Martin, MD, Fred Hutchinson Cancer Research Center
Cannabidiol for the Prevention of Graft-Versus-Host-Disease after Allogeneic Stem Cell Transplantation: Results of a Phase I/II Study
Moshe Yeshurun, MD, Rabin Medical Center;
Ofer Shpilberg, MD, Sackler School of Medicine;
Korina Herscovici, MD, Sackler School of Medicine;
Liat Shargian, MD, Institution of Hematology, Rabin Medical Center;
Juliet Dreyer, RN, Sackler School of Medicine;
Anat Peck, RN, Sackler School of Medicine;
Moshe Israeli, PhD, Rabin Medical Center;
Maly Levy-Assaraf, PhD, Sackler School of Medicine;
Tsipora Gruenewald, M.Ph.Sc, Rabin Medical Center;
Rafael Mechoulam, PhD, Hebrew University;
Pia Raanani, MD, Institution of Hematology, Rabin Medical Center;
Ron Ram, MD, Rabin Medical Center
Biomimetic Nanofibrous Mesh for Long-Term Preservation of Intestinal Epithelial Cells
Jenny Zilberberg, Ph.D., Hackensack University Medical Ctr;
Jennifer Matos, Ph.D., Hackensack University Medical Ctr;
Eugenia Dziopa, M.S., Hackensack University Medical Ctr;
Chao Jia, Stevens Institute of Technology;
Hongjun Wang, Ph.D., Stevens Institute of Technology;
Robert Korngold, PhD, Hackensack University Medical Center
![[Visit Client Website]](images/banner.gif)